Alzheimers disease(AD)is a highly complex neurodegenerative disorder of the aged that has multi-factors which contribute to its etiology in terms of initiation and progression[1].
Most of tumor treatment failure is ascribed to multidrug resistance,which involves in almost all types of tumors and with many clinical anticancer drugs.
3,4-Dihydro-2H-[1,4]diazepino[6,7,1-hi]-indol-1-ones(Ⅰ)were developed with the aid of protein structure-based drug design by Pfizer as the third generation of novel 5,6,7-tricyclic PARP-1 inhibitors.
A series of imidazo[1,2-a]pyridine derivatives against c-Met was designed by means of bioisosteric replacement.1 In our study,a selective,potent c-Met inhibitor,A41 was identified,with IC50 values of
Artemisinin was used as a drug repositioning prototype for the development of novel antitumor drugs.Spiro-heterocycle unit as a core fragment has been found to exhibit wide range of activities in a va